Trials / Unknown
UnknownNCT04809155
Girl2Girl: A Web-based Trial
A Reproductive Health Program for A Select Population
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 574 (estimated)
- Sponsor
- Center for Innovative Public Health Research · Academic / Other
- Sex
- Female
- Age
- 14 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
This is a pilot effectiveness study of Girl2Girl, a text messaging-based pregnancy prevention program for cisgender sexual minority adolescents.
Detailed description
An estimated one in four teen women will become pregnant by the time she is 20 years of age. That said, significant disparity in rates exist for lesbian, gay, bisexual and other sexual minority women (LGB) versus non-LGB teen women: Research suggests that lesbian and bisexual teen women are between two and four times more likely to report having been pregnant than teen women who identified as exclusively heterosexual. Despite this compelling evidence that lesbian and bisexual adolescent women are at risk for teen pregnancy, programs tailored to the unique needs of adolescent LGB women are nonexistent. Evidence-based teen pregnancy prevention (TPP) programs targeting LGB teen women are urgently needed. The Girl2Girl intervention text messaging-based TPP program designed specifically for LGB women ages 14-18 years, nation-wide. This is an extension of a previous randomized controlled trial. Here, the cohort was recruited using an effectiveness strategy: Girls were allowed to register and enroll themselves without needing to talk to research staff. All eligible and interested youth were allowed to enroll; no diversity targets were applied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Girl2Girl | The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later. |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2021-06-07
- Completion
- 2021-06-07
- First posted
- 2021-03-22
- Last updated
- 2021-03-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04809155. Inclusion in this directory is not an endorsement.